Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ferroptosis-IN-8 (Compound B4) is a potent and specific small molecule inhibitor of ferroptosis, demonstrating a half-maximal inhibitory concentration (IC50) of 40.49 nM. it suppresses RSL3- or FIN56-induced ferroptosis through robust antioxidant mechanisms, alleviates models of hepatorenal injury, and shows significant potential in preventing a spectrum of ferroptosis-related diseases.
Description | Ferroptosis-IN-8 (Compound B4) is a potent and specific small molecule inhibitor of ferroptosis, demonstrating a half-maximal inhibitory concentration (IC50) of 40.49 nM. it suppresses RSL3- or FIN56-induced ferroptosis through robust antioxidant mechanisms, alleviates models of hepatorenal injury, and shows significant potential in preventing a spectrum of ferroptosis-related diseases. |
Targets&IC50 | Ferroptosis:40.49 nM |
In vivo | Methods: Ferroptosis-IN-8 (10 mg/kg, intraperitoneal injection) was used to treat the acetaminophen-induced acute liver injury mouse model and its therapeutic effect was observed. Results: Ferroptosis-IN-8 can reduce the increase of plasma ALT and AST in mice and reduce the liver injury response caused by acetaminophen. [1] |
Synonyms | Ferroptosis IN8 |
Molecular Weight | 285.3 |
Formula | C15H15N3O3 |
Cas No. | 3056016-82-8 |
Smiles | O=C(NN=CC1=CC=C(OC)C=C1)C=2C=CC=C(O)C2N |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 40 mg/mL (140.2 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.